Viewing Study NCT07090369

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:10 PM
Ignite Modification Date: 2026-01-02 @ 12:46 AM
Study NCT ID: NCT07090369
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-07-29
First Post: 2025-07-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer
Sponsor: Peter MacCallum Cancer Centre, Australia
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Castrate Resistant Prostate Cancer (mCRPC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None prostate cancer View
None olaparib View
None pembrolizumab View
None 177Lu-PSMA View
None metastatic castrate resistant prostate cancer View
None triplet therapy View